Provider Alert! Temporary Change in PDL Status for Antihypertensives, Sympatholytics Drug ClassTexas Children's Health Plan
Date: September 26, 2022
Attention: All Providers
Effective Date: September 26, 2022
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: The Health and Human Services Commission (HHSC) is aware of a drug shortage for Catapres-TTS patches in the Antihypertensives, Sympatholytics drug class due to the discontinuation of this product by the manufacturer, Boehringer Ingelheim. HHSC received reports of a shortage from MCOs, and the manufacturer verified the shortage.
How this impacts providers: Effective September 26, 2022, HHSC temporarily removed the non-preferred status from the generic product, clonidine transdermal patches, on the preferred drug list (PDL). The preferred status of the brand name products (NDC 00597-0031-34, 00597-0032-34, and 00597-0033-34) will not change to allow for any existing stock available to be utilized.
HHSC removed the non-preferred status for the following generic drugs.
|NDC||Generic Drug Name|
|00378-0871-99||CLONIDINE 0.1 MG/DAY PATCH|
|00591-3508-04||CLONIDINE 0.1 MG/DAY PATCH|
|51862-0453-04||CLONIDINE 0.1 MG/DAY PATCH|
|00378-0872-99||CLONIDINE 0.2 MG/DAY PATCH|
|00591-3509-04||CLONIDINE 0.2 MG/DAY PATCH|
|51862-0454-04||CLONIDINE 0.2 MG/DAY PATCH|
|00378-0873-99||CLONIDINE 0.3 MG/DAY PATCH|
|00591-3510-04||CLONIDINE 0.3 MG/DAY PATCH|
|51862-0455-04||CLONIDINE 0.3 MG/DAY PATCH|
Next steps for providers: Prescribers should share this communication with their staff.
If you have any questions, please email Provider Network Management at: email@example.com.